Table 1.

Summary of mutation patterns in the PI3K pathway and KRAS in 221 endometrial cancers

  PTEN protein 
 PercentagePositiveNegativeMMR deficienta
All wild type26.24%15.38%10.86%8/43 (18.60%)
PTEN−/−2.26%0.00%2.26%0/5 (0%)
PTEN+/−6.79%3.17%3.62%2/10 (20%)
PIK3CA8.60%3.17%5.43%3/16 (18.75%)
PIK3R1/PIK3R24.07%1.36%2.71%2/8  (25%)
PIK3CA + PIK3R1/PIK3R20.90%0.45%0.45%0/2 (0%)
PTEN−/− + PIK3CA1.36%0.00%1.36%1/3 (33.33%)
PTEN+/− + PIK3CA14.93%9.05%5.88%9/30 (30%)
PTEN−/− + PIK3R1/PIK3R20.45%0.00%0.45%0/1 (0%)
PTEN+/− + PIK3R1/PIK3R27.24%4.98%2.26%3/15 (20%)
PTEN−/− + PIK3CA + PIK3R1/PIK3R20.45%0.00%0.45%0/1 (0%)
PTEN+/− + PIK3CA + PIK3R1/PIK3R17.69%3.17%4.52%5/17 (29.41%)
KRAS4.98%1.81%3.17%1/9 (11.11%)
KRAS + PTEN+/−1.81%0.90%0.90%2/4 (50%)
KRAS + PIK3CA3.62%1.81%1.81%1/8 (12.5%)
KRAS + PIK3R1/PIK3R22.71%0.90%1.81%1/5 (20%)
KRAS + PTEN+/− + PIK3CA3.17%1.36%1.81%3/6 (50%)
KRAS + PTEN+/− + PIK3R1/PIK3R20.90%0.45%0.45%1/2 (50%)
KRAS + PTEN+/− + PIK3CA + PIK3R1/PIK3R10.90%0.45%0.45%1/1 (100%)
AKT0.90%0.90%0.00%0/2 (0%)
  • Abbreviations: MMR, mismatch repair; PTEN +/−, PTEN heterozygous mutation; PTEN −/−, PTEN homozygous mutation.

  • a 188 endometrial tumor slides were available and were stained for the MMR proteins.